23,433 Shares of Avalyn Pharma Inc. $AVLN Bought by Profund Advisors LLC

Profund Advisors LLC bought a new stake in shares of Avalyn Pharma Inc. (NASDAQ:AVLN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 23,433 shares of the company’s stock, valued at approximately $668,000. Profund Advisors LLC owned approximately 0.05% of Avalyn Pharma as of its most recent SEC filing.

Several other large investors have also made changes to their positions in AVLN. China Universal Asset Management Co. Ltd. acquired a new position in shares of Avalyn Pharma during the third quarter valued at about $29,000. Manchester Capital Management LLC acquired a new position in shares of Avalyn Pharma during the 3rd quarter worth about $36,000. State Street Corp acquired a new stake in Avalyn Pharma in the second quarter worth $10,501,000. Braidwell LP acquired a new stake in shares of Avalyn Pharma during the second quarter worth about $26,382,000. Finally, Montanova Capital LLC acquired a new stake in shares of Avalyn Pharma during the second quarter worth $82,402,000.

Avalyn Pharma Price Performance

NASDAQ AVLN opened at $27.47 on Thursday. The business has a fifty day moving average of $29.47. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. Avalyn Pharma Inc. has a 12 month low of $22.24 and a 12 month high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.05. On average, equities research analysts forecast that Avalyn Pharma Inc. will post -3.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AVLN has been the subject of several research analyst reports. Raymond James Financial began coverage on shares of Avalyn Pharma in a report on Friday, October 2nd. They set an “outperform” rating and a $60.00 target price for the company. Weiss Ratings began coverage on Avalyn Pharma in a research note on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Wall Street Zen downgraded Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Finally, Morgan Stanley increased their price objective on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.00.

About Avalyn Pharma

Avalyn Pharma, Inc (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.